Irbetol CH Tablet contains Irbesartan 150 mg and Chlorthalidone 12.5 mg, a combination therapy used for the management of hypertension in patients who require more effective blood pressure control. It helps in lowering elevated blood pressure levels by combining the action of an angiotensin II receptor blocker with a thiazide-like diuretic. This dual mechanism supports better cardiovascular health and assists in reducing the long-term complications associated with uncontrolled hypertension.

Irbesartan works by blocking the action of angiotensin II, a substance that causes blood vessels to narrow. By relaxing and widening blood vessels, it helps improve blood flow and lower blood pressure. Chlorthalidone complements this effect by promoting the elimination of excess salt and water through urine, helping reduce fluid retention and decrease the workload on the heart. Together, the combination provides effective and sustained blood pressure management.

The formulation is commonly prescribed for individuals whose blood pressure is not adequately controlled with a single medication. Consistent blood pressure management is important in reducing the risk of serious cardiovascular events such as heart attack, stroke, kidney damage, and other hypertension-related complications. The combination offers convenience, improved treatment adherence, and reliable therapeutic outcomes when used as directed by a healthcare professional.

With the increasing prevalence of hypertension and cardiovascular disorders worldwide, Irbetol CH Tablet holds strong demand in the cardiology segment. Its clinically established combination, broad physician acceptance, and growing requirement for combination antihypertensive therapies make it a valuable product for retailers and distributors. The product offers excellent business potential and long-term growth opportunities within the cardiovascular healthcare market.

Irbetol CH Tablet is generally well tolerated when used as prescribed. Some individuals may experience dizziness, headache, fatigue, increased urination, weakness, nausea, electrolyte imbalance, low blood pressure, or mild gastrointestinal discomfort. Rarely, allergic reactions or significant changes in kidney function and electrolyte levels may occur.

Irbetol CH Tablet is indicated for the management of hypertension, uncontrolled high blood pressure requiring combination therapy, cardiovascular risk reduction, and supportive treatment to help prevent hypertension-related complications. It helps maintain healthy blood pressure levels and supports overall cardiovascular health.

This medication should be used only under the supervision of a qualified healthcare professional. Regular monitoring of blood pressure, kidney function, and electrolyte levels may be recommended during treatment. Patients with kidney disease, liver disease, dehydration, electrolyte abnormalities, or those taking other antihypertensive medications should consult their physician before use. Do not discontinue treatment without medical advice.

Store in a cool, dry place below 25°C, protected from moisture and direct sunlight. Keep the tablets in their original packaging and out of reach of children. Do not use after the expiry date or if the packaging is damaged or tampered with.